SCHEMBL5743598

SCHEMBL5743598

COc1cc2c(C=O)cnc(Cc3cccc(OC(C)C)c3)c2cc1OC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.44
HCRTR1 O43613 1/20 0.41
HCRTR2 O43614 1/20 0.41
GFPT1 Q06210 1/20 0.41
PDE10A Q9Y233 6/20 0.40
PDE3B Q13370 3/20 0.40
PDE3A Q14432 3/20 0.40
EGFR P00533 1/20 0.39
ERBB2 P04626 1/20 0.39
ERN1 O75460 1/20 0.38
HTT P42858 1/20 0.38
USP2 O75604 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
CYP3A4 P08684 2/20 0.38
MAPK1 P28482 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HIF1A Q16665 2/20 0.38
PDE2A O00408 1/20 0.38
ABCC4 O15439 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5744723 0.91 DHFR (0.38) DHFRPDE10APDE3BPDE3AEGFR
SCHEMBL5745105 0.83 ERN1 (0.46) ERN1HTTALDH1A1LMNASMN1; SMN2
SCHEMBL5745797 0.83 ERN1 (0.46) ERN1HTTALDH1A1LMNASMN1; SMN2
SCHEMBL5744687 0.83 ERN1 (0.42) DHFRPDE10APDE3BPDE3AERN1
SCHEMBL5745438 0.82 PDE10A (0.42) DHFRPDE10APDE3BPDE3AEGFR
SCHEMBL5743415 0.81 DHFR (0.50) DHFRHCRTR1HCRTR2GFPT1PDE10A
SCHEMBL5745483 0.81 DPP4 (0.53) DHFRGFPT1PDE10APDE4D
SCHEMBL5743602 0.80 PDE10A (0.41) PDE10APDE3BPDE3AHTTMTNR1A
SCHEMBL5746367 0.80 DPP4 (0.41) DHFRPDE10APDE3BPDE3AEGFR
SCHEMBL5745200 0.80 PDE10A (0.39) DHFRPDE10APDE3BPDE3AEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067529-B2 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors HOFFMANN-LA ROCHE INC. (US) 2006-06-27 US disclosed
EP-1631551-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-08 EP disclosed
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors BOLIN DAVID ROBERT (US) 2004-12-23 US disclosed
WO-2004101528-A2 ISOQUINOLINE DERIVATIVES AND THEIR USE AS GFAT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259910-A1 Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors GFPT1, GLS2, GLS DHFR 674/4885HCRTR1 3804/4885HCRTR2 3040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.